Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Tops, Bastiaan ^a   Normanno, Nicola ^b,c   Kurth, Henriette ^d   Amato, Eliana ^e   Mafficini, Andrea ^e   Rieber, Nora ^f   Le Corre, Delphine ^g   Rachiglio, Maria ^b   Reiman, Anne ^h   Sheils, Orla ⁱ   Noppen, Christoph ^d   Lacroix, Ludovic ^g   Cree, Ian A ^h   Scarpa, Aldo ^e   Ligtenberg, Marjolijn ^a   Laurent Puig, Pierre ^g  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c Centro di Ricerche Oncologiche di Mercogliano CROM   (Italy)

^d Department of Genetics/Molecular Biology ^*  (Switzerland)

^e UNIVERSITY OF VERONA   (Italy)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^g INSERM   (France)

^h UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

ⁱ TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Colorectal cancer; Ion torrent; Multiplex PCR; Next generation sequencing; Non small cell lung cancer; Semi conductor sequencing

Indexed keywords

B RAF KINASE; PROTEIN TYROSINE KINASE;

ACCURACY; AMPLICON; ARTICLE; BRAF GENE; COLORECTAL CANCER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS SOFTWARE; DIAGNOSTIC KIT; EGFR GENE; FEASIBILITY STUDY; GENE; GENE FREQUENCY; GENE MUTATION; GENE POOL; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; GENOTYPING TECHNIQUE; MOUSE; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATION RATE; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; NONHUMAN; ONCOGENE K RAS; POLYMERASE CHAIN REACTION SYSTEM; PROCESS DEVELOPMENT; REPRODUCIBILITY; SEMI CONDUCTOR SEQUENCING; SENSITIVITY ANALYSIS; TURNAROUND TIME; COLON TUMOR; DNA MUTATIONAL ANALYSIS; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN; LUNG TUMOR; MUTATION; PROCEDURES;

COLONIC NEOPLASMS; DNA MUTATIONAL ANALYSIS; GENOTYPING TECHNIQUES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATION; MUTATION RATE; REPRODUCIBILITY OF RESULTS;

EID: 84924139134     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1015-5     Document Type: Article

References (22)

1. Mendelsohn J. Personalizing oncology: perspectives and prospects. J Clin Oncol. 2013;31(15):1904-11.
2. Douillard J-Y, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369(11):1023-34.
3. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947-57.
4. Normanno N, Rachiglio AM, Roma C, Fenizia F, Esposito C, Pasquale R, et al. Molecular diagnostics and personalized medicine in oncology: Challenges and opportunities. J Cell Biochem. 2013;114(3):514-24.
5. Garraway LA. Genomics-Driven Oncology: Framework for an Emerging Paradigm. J Clin Oncol. 2013;31(15):1806-14.
6. Li TH, Kung HJ, Mack PC, Gandara DR. Genotyping and Genomic Profiling of Non-Small-Cell Lung Cancer: Implications for Current and Future Therapies. J Clin Oncol. 2013;31(8):1039-49.
7. Coghlin CL, Smith LJ, Bakar S, Stewart KN, Devereux GS, Nicolson MC, et al. Quantitative analysis of tumour in bronchial biopsy specimens. J Thorac Oncol. 2010;5(4):448-52.
8. Dienstmann R, Rodon J, Barretina J, Tabernero J. Genomic medicine frontier in human solid tumors: prospects and challenges. J Clin Oncol. 2013;31(15):1874-84.
9. Tian S, Simon I, Moreno V, Roepman P, Tabernero J, Snel M, et al. A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. Gut. 2013;62(4):540-9.
10. Yokota T, Ura T, Shibata N, Takahari D, Shitara K, Nomura M, et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer. 2011;104(5):856-62.
11. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature. 2007;448(7152):439-44.
12. Day E, Waters B, Spiegel K, Alnadaf T, Manley PW, Buchdunger E, et al. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol. 2008;599(1-3):44-53.
13. Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Canc Discov. 2011;1(1):78-89.
14. Arcila ME, Chaft JE, Nafa K, Roy-Chowdhuri S, Lau C, Zaidinski M, et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Canc Res. 2012;18(18):4910-8.
15. De Greve J, Teugels E, Geers C, Decoster L, Galdermans D, De Mey J, et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer. 2012;76(1):123-7.
16. Mazieres J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. 2013;31(16):1997-2003.
17. Williams C, Ponten F, Moberg C, Soderkvist P, Uhlen M, Ponten J, et al. A high frequency of sequence alterations is due to formalin fixation of archival specimens. Am J Pathol. 1999;155(5):1467-71.
18. Endris V, Penzel R, Warth A, Muckenhuber A, Schirmacher P, Stenzinger A, et al. Molecular diagnostic profiling of lung cancer specimens with a semiconductor-based massive parallel sequencing approach: feasibility, costs, and performance compared with conventional sequencing. The Journal of molecular diagnostics. 2013;15(6):765-75.
19. Beadling C, Neff TL, Heinrich MC, Rhodes K, Thornton M, Leamon J, et al. Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping. The Journal of molecular diagnostics: JMD. 2013;15(2):171-6.
20. Hadd AG, Houghton J, Choudhary A, Sah S, Chen L, Marko AC, et al. Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. The Journal of molecular diagnostics: JMD. 2013;15(2):234-47.
21. Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang JJ, Xu CR, et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2011;29(24):3316-21.
22. Morabito A, Costanzo R, Rachiglio AM, Pasquale R, Sandomenico C, Franco R, et al. Activity of Gefitinib in a Non-Small-Cell Lung Cancer Patient with Both Activating and Resistance EGFR Mutations. J Thorac Oncol. 2013;8(7):e59-60.